Evercore ISI Group Upgrades Enanta Pharmaceuticals to Outperform, Announces $62 Price Target

Evercore ISI Group analyst Liisa Bayko upgrades Enanta Pharmaceuticals (NASDAQ:ENTA) from In-Line to Outperform and announces $62 price target.

Evercore ISI Group analyst Liisa Bayko upgrades Enanta Pharmaceuticals (NASDAQ:ENTA) from In-Line to Outperform and announces $62 price target.

Total
0
Shares
Related Posts